Emboldened by Dupixent COPD win, Sanofi execs pitch leading immunology's next era
Since launching in 2017, Dupixent has racked up a range of approvals on its path to becoming Sanofi’s best-selling drug.
On Sunday, Sanofi and Regeneron …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
